Navigation Links
Significant Anti-Tumor Activity and Extended Half-Life of NKTR-102 (PEG-irinotecan) Highlighted in Phase 1 Data Presented at EORTC-NCI-AACR Symposium
Date:10/24/2008

Active metabolite concentrations of NKTR-102 significantly more sustained

in between doses than possible with irinotecan

GENEVA and SAN CARLOS, Calif., Oct. 24 /PRNewswire-FirstCall/ -- Nektar Therapeutics (Nasdaq: NKTR) today reported positive Phase 1 data for its lead proprietary oncology product candidate, NKTR-102 (PEG-irinotecan). The data were presented at the 20th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics in Geneva, Switzerland, and highlighted the significant anti-tumor activity and superior pharmacokinetic profile of NKTR-102. NKTR-102 leverages Nektar's innovative small molecule PEGylation platform and is currently in Phase 2 clinical development.

"NKTR-102 is an excellent example of how our proprietary PEGylation platform allows us to precisely modify an oncolytic with sub-optimal pharmacokinetics and enhance its therapeutic profile," said Randall Moreadith, M.D. Ph.D., Chief Development Officer and Senior Vice President of Drug Development of Nektar. "In our Phase 1 study, we established our desired pharmacokinetic profile with NKTR-102 -- and in particular -- a substantially prolonged half-life relative to standard irinotecan. These Phase 1 data underscore the importance of our clinical development strategy, which includes additional indications for which irinotecan was never developed, such as ovarian, cervical, and breast cancers. We are excited about the potential of NKTR-102 to dramatically expand therapeutic options for oncologists and improve survival rates for patients with a variety of cancers."

Of the 57 patients in total from all dose schedules, 13 reported significant anti-tumor activity. Seven patients had confirmed partial responses (greater than 30 p
'/>"/>

SOURCE Nektar Therapeutics
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6

Related biology technology :

1. BioElectronics Announces Significant Progress in Canadian and International Distribution
2. DuPont Meeting Significant 2008 Milestones in Progressing Advanced Biofuels
3. Animetrics Inc. Named One of Business NH Magazine's '10 Companies to Watch' for its Significant Revenue Growth
4. Bucindolol Significantly Reduces Hospitalization and Death in Heart Failure Patients With Very Favorable Genotypes
5. Enobia Pharma Presents PreClinical Data Showing ENB-0040 Significantly Improved Survival and Healed Skeletal Manifestations of Severe Hypophosphatasia in Mice
6. Phlo Affiliate Announces Significant Distribution Expansion In California
7. On the boil: New nano technique significantly boosts boiling efficiency
8. In a Year of Unprecedented Growth for Biotechnology Innovation, Targeted Therapies Gain Most Significant Traction, According to New Deloitte Study
9. Phase 3 studies show golimumab significantly improved signs and symptoms of rheumatoid arthritis
10. Video: Data From 185,000 ICU Admissions Show Significant Reductions in Mortality:
11. Treatment with Paliperidone ER May Be Associated with Significantly Reduced Use of Mental Health Resources

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/19/2009)...RNewswire-FirstCall/ -- Omeros Corporation (Nasdaq...lts for the third quarter ended September 30, 2009...meros reported a net loss of $3.9 million, or $1.3...lion, or $2.54 per share, for the same period in 2... the Company reported a net loss of $15.5 million,...
(Date:11/19/2009)...A, Md., Nov. 19 Spherix ...technology for diabetes therapy, and a provider of...ood, supplement, biotechnology and pharmaceutical ...y reported $6.3 million registered direct placemen...f its common stock and warrants to purchase up to ...
(Date:11/19/2009)... 19 Spherix Incorporated...or diabetes therapy, and a provider of technical a...ent, biotechnology and pharmaceutical companies, t...ting of Shareholders. ,, At the meeting, shareh...ected the following members to the Board of Direct...
(Date:11/19/2009)...many, November 19 MONITORING FORCE...6th, 2009 Flibanserin in the,indication treatment-...s,disease for orphan drug status designation with ...uced dyskinesia is a complication of the mainstay,...rden to some of those,affected, since it may be di...
Breaking Biology Technology:Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights 2Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights 3Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights 4Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights 5Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights 6Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights 7Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights 8Spherix Announces the Closing of $6.3 Million Registered Direct Offering 2Spherix Announces the Closing of $6.3 Million Registered Direct Offering 3Spherix Announces Results of Annual Shareholders Meeting 2Spherix Announces Results of Annual Shareholders Meeting 3Spherix Announces Results of Annual Shareholders Meeting 4MONITORING FORCE GmbH Requests Acknowledgment of Flibanserin as "Orphan Drug" 2
...ences, Inc. (Nasdaq: SGMO ), the world leader in...inding proteins (ZFPs), announced today that it ha...ons grant from the Bill & Melinda Gates Founda... health research project conducted by Sangamo scie...ivo Treatment of HIV Infection." , , Sangamo,s p...
...n, an orthopedic implants company focused on silic...hat it has received a CE (Conformite Europeene) ma...ral spacers using novel CSC (cancellous-structured...ing Amedica,s novel silicon nitride ceramic, offer...d to promote bony fusion. , , The Valeo family ...
...accine is available now for testing worldwide, fro...cine based on the same Replikins peptide technolog...year ago that the current H1N1 outbreak/pandemic w...unique advantage of the Replikins vaccine is its r...ated that conventionally developed H1N1 vaccines w...
Other Biology Technology:Sangamo BioSciences Receives $100,000 Grand Challenges Explorations Grant for Innovative Global Health Research 2Sangamo BioSciences Receives $100,000 Grand Challenges Explorations Grant for Innovative Global Health Research 3Sangamo BioSciences Receives $100,000 Grand Challenges Explorations Grant for Innovative Global Health Research 4Amedica Receives CE Mark for Valeo(TM) Ceramic Spinal Implant System Incorporating CSC Technology 2First H1N1 Swine Flu Vaccine, Replikins-Based, Is Ready Now for Testing Worldwide 2
(Date:11/20/2009)...p of University of Oklahoma researchers were seque...man genome project. Today, the OU Advanced Cente...rnational effort to sequence the tomato genome wit...ence Foundation for plant genomics. , "The toma...ving the tomato and crop yields will improve quali...
(Date:11/20/2009)..., November 19, 2009 The estimated 4.6 million Ame...isk of developing respiratory symptoms due to poor...onnaire study undertaken earlier this year by inve... Veterinary Medicine. , The studywhich polled mo...t 50 percent of individuals working in barns compl...
(Date:11/20/2009)...ilable in German . , In the current online ...Dr. Stefanie Eyerich and Dr. Kilian Eyerich togeth...don and Istituto Dermopatico dell,Immacolata in Ro...resents a milestone on the way to developing new t...ch as psoriasis and allergic reactions and potenti...
Breaking Biology News(10 mins):NSF awards $7.5M grant to University of Oklahoma for plant genomics 2Barn personnel experience higher-than-average rates of respiratory symptoms 2Discovery of new type of immune cells regulating inflammation in chronic diseases 2Plainview Milk Products Cooperative Institutes New Policies and Procedures 51367 1Plainview Milk Products Cooperative Institutes New Policies and Procedures 51367 2Pioneer Surgical Technology Inc Names Thomas J McLeer as Chief Marketing Officer and General Manager of Spinal Operations 51364 1Pioneer Surgical Technology Inc Names Thomas J McLeer as Chief Marketing Officer and General Manager of Spinal Operations 51364 2Blue Cross and Blue Shield of Illinois Urges Constant Vigilance Against Growing Threat of Killer Superbug 51361 1Blue Cross and Blue Shield of Illinois Urges Constant Vigilance Against Growing Threat of Killer Superbug 51361 2Blue Cross and Blue Shield of Illinois Urges Constant Vigilance Against Growing Threat of Killer Superbug 51361 3
...URHAM, N.H. Stacia Sower, professor of biochemist...mparative Endocrinology at the University of New H...ational Science Foundation (NSF) for research on b...h the four-year grant, Sower will build upon her d...monal genomics and proteomics. Sower defines the p...
...hen a single female is nearby, female antbirds wil... apparent attempt to keep their messages from gett...nline on March 12th in Current Biology , a Cell P...on by singing a different tune. , The findings of...and "jamming avoidance" occur between mates, accor...
...IRMINGHAM, Ala. -- University of Alabama at Birmin...ive a top international award in nephrology, the L...ment in the Understanding of Polycystic Kidney Dis...rnational Society of Nephrology. , She was cited ...ycystic kidney disease (PKD) research, clinical pr...
Other Biology News:Major NSF grant boosts UNH research on hormonal genomics 2Female birds 'jam' their mates' flirtatious songs 2UAB's Lisa Guay-Woodford earns top international nephrology prize 2UAB's Lisa Guay-Woodford earns top international nephrology prize 3
acridine orange 10-nonyl bromide (nonyl acridine orange) from Molecular Probes (Invitrogen)
Rabbit Anti-dansyl Polyclonal Antibody, Unconjugated from Molecular Probes (Invitrogen)
propidium iodide *FluoroPure™ grade* from Molecular Probes (Invitrogen)
Mouse Anti-Rat RT1Ac (Class I Polymorphic) Monoclonal Antibody, Unconjugated from AbD Serotec
Biology Products: